Real-world efficacy and safety profile of four JAK inhibitors in rheumatoid arthritis: a French single-center observational study

Study limitation reported by the research below: “Tofacitinib subgroup was very small (n=10), so any efficacy or safety conclusions for that agent alone should be interpreted with caution.”